Eradivir, a preclinical biotech company ... which is broader than the current standard of care. A research paper titled “Targeted recruitment of immune effector cells for rapid eradication of ...
Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and ...
The data from these studies will inform the next stages of preclinical research, including Good Laboratory Practice (GLP) enabling studies and future clinical development. While InvestingPro ...
A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...
INDIANAPOLIS — GeniPhys, a preclinical-stage company developing regenerative collagen polymeric biomaterials for soft tissue restoration, has been awarded a $500,000 National Science Foundation (NSF) ...